Predictive Factors for Tumor Progression in Non-Functioning Pituitary Macroadenomas Post-Surgery

Overview

This retrospective study of 212 patients identified preoperative and postoperative tumor volumes as key predictors of progression in residual non-functioning pituitary macroadenomas after transnasal transsphenoidal surgery. A tumor volume cutoff of 7.12 cm3 effectively distinguished stable from progressive residual tumors, aiding individualized follow-up and treatment decisions.

Background

Non-functioning pituitary macroadenomas (NFPMAs) are common intracranial tumors that often require surgical resection due to mass effect symptoms. Complete tumor removal is critical for long-term control but is achieved in only about 60% of cases. Residual tumor tissue may remain stable or progress postoperatively, but factors predicting these outcomes are not well defined. This study aimed to identify clinical and radiological predictors of tumor progression to optimize postoperative management.

Data Highlights

Key Findings

• Gross total resection was achieved in 44.3% of patients, but 15.1% experienced recurrence after initial GTR.
• Among patients with residual tumor, 64.4% remained stable while 35.6% showed progression over a mean follow-up of 39 months.
• Preoperative tumor volume was significantly larger in patients with progressive residuals (median 11.6 cm3) compared to stable residuals (median 5.81 cm3; p < 0.001).
• ROC analysis identified a tumor volume cutoff of 7.12 cm3 to distinguish stable from progressive residual tumors (AUC = 0.748).
• No significant differences were found between stable and progressive groups in Hardy or Knosp tumor classifications.
• Postoperative morning serum cortisol levels were nominally higher in patients with progressive residuals (14.10 μg/dL vs. 10.83 μg/dL; p = 0.022), though this finding is exploratory.

Clinical Implications

Preoperative and early postoperative tumor volumes can serve as practical prognostic markers to stratify patients at risk for tumor progression after surgery for NFPMAs. Using a volume cutoff of 7.12 cm3 may help clinicians tailor follow-up imaging intervals and consider early adjuvant therapies for high-risk patients. Routine assessment of postoperative cortisol levels might provide additional, though preliminary, prognostic information.

Conclusion

This study highlights tumor volume as a key predictor of progression in residual NFPMAs following transnasal transsphenoidal surgery. Incorporating volumetric assessment into postoperative management may improve individualized patient care and outcomes.

References

1. Single-Center Retrospective Study 2023 -- Assessing Factors Influencing Tumor Progression in NFPMAs After Surgery